Protocol Ledger

NCT03894215 · Phase II · TERMINATED

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Interventional Phase II clinical trial protocol NCT03894215 sponsored by Agenus in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-01 Enrollment: 211 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03894215
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)211 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03894215
Protocol FieldVerified Registry Value
NCT IdentifierNCT03894215
Consolidated Lead SponsorAgenus
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment211 participants (ACTUAL)
Registered Start Date2019-06-01
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI